Antibiotic Resistance: The Need For a Global Strategy

Journal of Pharmaceutical Sciences

Volumn 105, Issue 8, 2016, Pages 2278-2287

  Elder, David P ^a   Kuentz, Martin ^b   Holm, René ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

^c H LUNDBECK A S   (Denmark)

Author keywords

antiinfectives; drug resistance; drug like properties; formulation; global health

Indexed keywords

ANTIBIOTIC AGENT; COUNTERFEIT DRUG; ANTIINFECTIVE AGENT; PRESCRIPTION DRUG;

ANTIBIOTIC RESISTANCE; DRUG APPROVAL; DRUG COST; DRUG RESEARCH; DRUG TARGETING; HEALTH PROGRAM; NOTE; WORLD HEALTH ORGANIZATION; BACTERIAL INFECTION; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG UTILIZATION REVIEW; ECONOMICS; HUMAN; INTERNATIONAL COOPERATION; MICROBIOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION REVIEW; HUMANS; INTERNATIONAL COOPERATION; PRESCRIPTION DRUGS;

EID: 84978877845     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2016.06.002     Document Type: Note

References (82)

1. 1 Tatem, A.J., Rogers, D.J., Hay, S.I., Global transport networks and infectious disease spread. Adv Parisitol 62 (2006), 293–343.
2. 2 Taubenberger, J.K., Morens, D.M., 1918 influenza: the mother of all pandemics. Rev Biomed 17 (2006), 69–79.
3. 3 Tatem, A., Pandemics: a deadly business. Nature, 488, 2012, 153.
4. 4 Woolhouse, M.E.J., Epidemiology: emerging diseases go global. Nature 451:21 (2008), 898–899.
5. 5 WHO. Global Forum for Health Research: The 10/90 Report on Health Research 2000–2001. 2001.
6. 6 DiMasi, J.A., Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs, Tufts Center for the Study of Drug Development. 2014 Available at: http://csdd.tufts.edu/files/uploads/Tufts_CSDD_briefing_on_RD_cost_study_-_Nov_18_2014.pdf Accessed March 15, 2016.
7. 7 Kakkar, A.K., Dahiya, N., The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space. Drug Develop Res 75 (2014), 231–234.
8. 8 Rex, J.H., Goldberger, M., Eisenstein, B.I., Harney, C., The evolution of the regulatory framework for antibacterial agents. Ann N Y Acad Sci 1323 (2014), 11–21.
9. 9 Tomassi, R., Brown, D.G., Walkup, G.K., Manchester, J.I., Miller, A.A., ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov 14 (2015), 529–541.
10. 10 FDA approves new antibacterial drug Avycaz. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm. Accessed March 15, 2016.
11. 11 Garber, K., A β-lactamase inhibitor revival provides new hope for old antibiotics. Nat Revs Drug Disc 14 (2015), 445–447.
12. 12 Guidance for Industry and Review Staff. Target Product Profile — a Strategic Development Process Tool, 2007, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Washington, DC Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm080593.pdf Accessed March 15, 2016.
13. 13 Perez, F., Salata, R.A., Bonomo, R.A., Current and novel antibiotics against resistant Gram-positive bacteria. Infect Drug Resist 1 (2008), 27–44.
14. 14 Desai, D., Wang, J., Wen, H., Li, X., Timmins, P., Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol 18:6 (2013), 1265–1276.
15. 15 Baker, S.J., Ding, C.Z., Akama, T., Zhang, Y.K., Hernandez, V., Xia, Y., Therapeutic potential of boron-containing compounds. Future Med Chem 1 (2009), 1275–1288.
16. 16 van der Meer, J.W.M., Fears, R., Davis, S.C., ter Meulen, V., Antimicrobial innovation: combining commitment, creativity and coherence. Nat Rev Drug Discov 13 (2014), 709–710.
17. 17 Clift, C., Gopinathan, U., Morel, C., Outtersen, K., Røttingen, J.-A., So, A., Towards a New Global Business Model for Antibiotics. Delinking Revenues from Sales. Chatham House (The Royal Institute of International Affairs), 1–4, October 2015. 2015.
18. 18 Payne, D.J., Gwynn, M.N., Holmes, D.J., Pompliano, D.L., Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6 (2007), 29–40.
19. 19 Lipinski, C.H., Lombardo, F., Dominy, B.W., Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Dev Rev 46 (2001), 3–26.
20. 20 Zhan, M.Q., Wilkinson, B., Drug discovery beyond the “rule-of-five”. Curr Opp Biotech 18 (2007), 478–488.
21. 21 Brown, D.G., Lister, T., May-Dracka, T.L., New natural products as leads for antibacterial drug discovery. Bioorg Med Chem Lett 24 (2014), 413–418.
22. 22 Katsnelson, A., New twist on antibiotic hunt hits pay dirt. Nat Rev Drug Discov 14 (2015), 153–154.
23. 23 Ling, L.L., Schneider, T., Peoples, A.J., et al. A new antibiotic kills pathogens without detectable resistance. Nature 517 (2015), 455–459.
24. 24 President's Council of Advisors on Science and Technology. Report to the President on Combating Antibiotic Resistance. September 2014. 2014 Available at: https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf Accessed March 15, 2016.
25. 25 Innovative Medicines Initiative. Available at: http://www.imi.europa.eu/. Accesssed March 15, 2016.
26. 26 Drive – AB. Reinvestment in R&D and responsible use of antibiotics. Available at: http://drive-ab.eu/. Accessed March 15, 2016.
27. 27 O'Neill, J., Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. The Review on Antimicrobial Resistance, 2014 Available at: http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf Accessed March 15, 2016.
28. 28 Chen, L.H., Wilson, M.E., The globalization of healthcare: implications of medical tourism for the infectious disease clinician. Emerg Infect 57 (2013), 1752–1759.
29. 29 Lee, V.C., Balaban, V., Medical Tourism. 2014 Available at: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-2-the-pre-travel-consultation/medical-tourism Accessed March 15, 2016.
30. 30 Smith, R.D., Chanda, R., Tangcharoensathien, V., Trade in health-related services. Lancet 373 (2009), 593–601.
31. 31 Martin-Davila, P., Fortun, J., Lopez-Velez, R., et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 21 (2008), 60–96.
32. 32 Molton, J.S., Tambayah, P.A., Ang, B.S., Ling, M.L., Fisher, D.A., The global spread of healthcare associated multi-drug resistant bacteria: a perspective from Asia. Clin Infect Dis 56 (2013), 1310–1318.
33. 33 Jean, S.S., Hsueth, P.R., High burden of antimicrobial resistance in Asia. Int J Antimicrobiol Agents 37 (2011), 291–295.
34. 34 Rogers, B.A., Aminzadeh, Z., Hayashi, Y., Paterson, D.L., Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. Clin Infect Dis 53 (2011), 49–56.
35. 35 Wilson, M.E., Chen, L.H., NDM-1 and the role of travel in its dissemination. Curr Infect Dis Rep 14 (2012), 213–226.
36. 36 FDA. Available at: http://blogs.fda.gov/fdavoice/index.php/tag/gain-act/, 2015 Accessed March 13, 2016.
37. 37 Antibacterial Drug Development Task Force. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm317207.htm. Accessed March 13, 2016.
38. 38 Biomarkers Consortium. Available at: http://www.biomarkersconsortium.org/. Accessed March 13, 2016.
39. 39 Foundation for the National Institute of Health. Available at: http://www.fnih.org/. Accessed March 13, 2016.
40. 40 Clinical Trials Transformation Initiative (CTTI). Available at: http://www.ctti-clinicaltrials.org/. Accessed March 13, 2016.
41. 41 New Drugs 4 Bad Bugs (ND4BB). Available at: http://www.imi.europa.eu/content/nd4bb. Accessed March 13, 2016.
42. 42 TRANSLOCATION. Molecular basis of the bacterial cell wall permeability. Available at: http://www.imi.europa.eu/content/translocation. Accessed March 13, 2016.
43. 43 ENABLE. European Gram-negative Antibacterial Engine. Available at: http://www.imi.europa.eu/content/enable. Accessed March 13, 2016.
44. 44 COMBACTE. Combatting Bacterial Resistance in Europe. Available at: http://www.imi.europa.eu/content/combacte. Accessed March 13, 2016.
45. 45 COMBACTE-CARE. Combatting Bacterial Resistance in Europe–Carbapenem Resistance. Available at: http://www.imi.europa.eu/content/combacte-care. Accessed March 13, 2016.
46. 46 COMBACTE-MAGNET. Combatting bacterial resistance in Europe–molecules against Gram negative infections. Available at: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=29528. Accessed March 13, 2016.
47. 47 iABC. Inhaled antibiotics in bronchiectasis and cystic fibrosis. Available at: http://www.imi.europa.eu/content/iabc. Accessed March 13, 2016.
48. 48 Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). Available at: http://www.jpiamr.eu/. Accessed March 13, 2016.
49. 49 Anti-infective agents. Available at: https://www.monash.edu/pharm/research/areas/drug-delivery/research-areas/anti-infective-agents. Accessed March 13, 2016.
50. 50 European Centre for Disease Prevention and Control. Available at: http://ecdc.europa.eu/en/Pages/home.aspx. Accessed March 13, 2016.
51. 51 Centers for Disease Control and Prevention (CDC). Available at: http://www.cdc.gov/. Accessed March 13, 2016.
52. 52 Infectious Diseases Society of America (IDSA), Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 52 (2011), S397–S428.
53. 53 EASAC. Available at: http://www.easac.eu/home.html. Accessed March 13, 2016.
54. 54 EASAC. Workshop on “Antimicrobial Drug Discovery, Greater Steps Ahead”, 07.03.14. Available at: http://www.easac.eu/home/press-releases/detail-view/article/workshop-on.html?cHash=3e9e8bf03be8984dc966f1510406c4ee&no_cache=1&sword_list%5B0%5D=antibiotics&sword_list%5B1%5D=greater&sword_list%5B2%5D=steps&sword_list%5B3%5D=ahead. Accessed March 16, 2016.
55. 55 EASAC. Infectious diseases and the future: policies for Europe, 04.11.11. Summ EASAC Report: Eur Public Health Innovation Policy Infect Dis: The View from EASAC. Available at: http://www.easac.eu/biosciences/reports-and-statements/detail-view/article/infectious-d-1.html?cHash=4d3d547599a6c07a560351bf783e2dc0&no_cache=1&sword_list%5B0%5D=infectious&sword_list%5B1%5D=diseases&sword_list%5B2%5D=the&sword_list%5B3%5D=future. Accessed March 16, 2016.
56. 55 EASAC. Healthcare-associated infections: the view from EASAC, 20.04.09. Available at: http://www.easac.eu/home/reports-and-statements/detail-view/article/healthcare-a.html?cHash=4818e32fec035200c35ee6a8943f61d9&no_cache=1&sword_list%5B0%5D=health&sword_list%5B1%5D=care&sword_list%5B2%5D=associated&sword_list%5B3%5D=infections. Assessed March 16, 2016.
57. 56 WHO, 19th WHO Model List of Essential Medicines. 2015 Available at: http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf Accessed on 13 March 2016.
58. 57 WHO. Worldwide country situation analysis: Response to antimicrobial resistance. http://www.who.int/drugresistance/documents/situationanalysis/en/. Accessed March 13, 2016.
59. 58 WHO, Global action plan on antimicrobial resistance. http://www.who.int/drugresistance/global_action_plan/en/. Accessed March 13, 2016.
60. 59 Global Antibiotic Resistance Program (GARP). Available at: http://www.cddep.org/garp/home. Accessed March 13,2016.
61. 60 Center for Disease Dynamics, Economics & policy (CDDEP). Available at: http://www.cddep.org/. Accessed March 13, 2016.
62. 61 Gelband, H., The global antibiotic resistance partnership. AMR Control, 2015, 98–101.
63. 62 Community for open antimicrobial drug discovery (CO-ADD). Available at: http://www.co-add.org/. Accessed March 13, 2016.
64. 63 Cooper, M.A., A community-based approach to new antibiotic discovery. Nat Revs Drug Discov 14 (2015), 587–588.
65. 64 The Wellcome Trust. Seeding Drug Discovery. Available at: http://www.wellcome.ac.uk/Funding/Innovations/Awards/Seeding-Drug-Discovery/index.htm. Accessed March 13, 2016.
66. 65 US National Institute of Allergy and Infectious Diseases R21/R33 awards. Available at: https://www.niaid.nih.gov/researchfunding/sop/pages/r21r33.aspx. Assessed March 13, 2016.
67. 66 What is systems biology? Available at: https://www.systemsbiology.org/about/what-is-systems-biology/. Accessed March 13, 2016.
68. 67 WHO. Substandard, Spurious, Falsely Labelled, Falsified and Counterfeit (SSFFC) Medical Products. 2016 Available at: http://www.who.int/mediacentre/factsheets/fs275/en/ Accessed March 13, 2016.
69. 68 Dégardin, K., Roggo, Y., Margot, P., Understanding and fighting the medicine counterfeit market. J Pharm Biomed Anal 87 (2014), 167–175.
70. 69 Harris, J., Stevens, P., Morris, J., Keeping it Real. Combatting the Spread of Fake Drugs in Poor Countries. 2009, International Policy Network Available at: http://www.africanliberty.org/pdf/Keepingitreal.pdf Accessed November 8, 2015.
71. 70 Seiter, A., Health and economic consequences of counterfeit drugs. Clin Pharmacol Ther 85 (2009), 576–578.
72. 71 Ambroise-Thomas, P., The tragedy caused by fake antimalarial drugs. Mediterr J Hematol Infect Dis, 4, 2012, e2012027.
73. 72 PSI. Pharmaceutical Security Institute (PSI), Washington, DC, 2014. Available at: http://www.psi-inc.org/counterfeitsituation.cfm. Accessed December 1, 2015.
74. 73 European Alliance for Access to Safe Medicine. Counterfeiting the Counterfeiter. 2012 Available at: http://www.eaasm.eu/cache/downloads/av3r9l87z4wg4ocs8w84gogs0/CtC%20report%202012.pdf Accessed March 16, 2016.
75. 74 European Alliance for Access to Safe Medicine. 2016. Available at: http://www.eaasm.eu/home,en. Accessed March 16, 2016.
76. 75 Siva, N., Tackling the booming trade in counterfeit drugs. The Lancet 376 (2010), 1725–1726.
77. 76 Mackey, T.K., Liang, B.A., The global counterfeit drug trade: patient safety and public health risks. J Pharm Sci 100 (2011), 4571–4579.
78. 77 mPEDIGREE. Bringing Quality to Life. 2016 Available at: http://mpedigree.net/ Accessed March16, 2016.
79. 78 IMPACT (International Products Anti-Counterfeiting Taskforce), Counterfeit drugs kill! WHO, 2008. Available at: http://www.who.int/impact/FinalBrochureWHA2008a.pdf. Accessed November 08, 2015.
80. 79 MEDICRIME. The international convention of the Council of Europe as a tool to combat counterfeit medicines. Available at: http://ec.europa.eu/food/training_strategy/news/docs/2728022012_d2_9_kristian_bartholin_a_possible_convention_at_international_level_en.pdf. Accessed March 16, 2016.
81. 80 Operation Pangea. Available at: http://www.interpol.int/Crime-areas/Pharmaceutical-crime/Operations/Operation-Pangea. Accessed March 16, 2016.
82. 81 Interpol. Available at: http://www.interpol.int/Crime-areas/Pharmaceutical-crime/Operations/Operation-Pangea. Accessed March 16, 2016.